Accuray Incorporated has received $-0.07 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 3 Financial Advisor in the Stock Trading Firms. Among 3 Analysts, Bottom line EPS Estimate for the current quarter is $-0.08 while the top line estimate is $-0.06 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 12.5%.
Accuray Incorporated results fell short with a surprise EPS of -20% or $-0.02. The Actual EPS was $-0.12 compared to the Estimated EPS of $-0.1 during its most recent quarterly earnings.
In the last quarter, Accuray Incorporated reported Annual Earnings of $-0.12. Based on the filings, last years Annual Earnings was, $-0.32. In the last Quarter, ARAY reported a surprise Earnings per Share of -20% . The consensus estimate for current quarter is $-0.07 and for the current fiscal year, the estimate is $-0.15. For the Next fiscal year, the estimate is $0.04 based on the consensus.
Accuray Incorporated (NASDAQ:ARAY) : On Tuesday heightened volatility was witnessed in Accuray Incorporated (NASDAQ:ARAY) which led to swings in the share price. The stock opened for trading at $5.45 and hit $5.75 on the upside , eventually ending the session at $5.75, with a gain of 4.55% or 0.25 points. The heightened volatility saw the trading volume jump to 1,775,062 shares. The 52-week high of the share price is $6.39 and the company has a market cap of $470 million. The 52-week low of the share price is at $4.45 .
ACCURAY INCORPORATED based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 130 systems have been installed in leading hospitals in the Americas, Europe and Asia.